[go: up one dir, main page]

NI201800039A - Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue - Google Patents

Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue

Info

Publication number
NI201800039A
NI201800039A NI201800039A NI201800039A NI201800039A NI 201800039 A NI201800039 A NI 201800039A NI 201800039 A NI201800039 A NI 201800039A NI 201800039 A NI201800039 A NI 201800039A NI 201800039 A NI201800039 A NI 201800039A
Authority
NI
Nicaragua
Prior art keywords
inhibitors
compounds
mono
dengue
disustituted
Prior art date
Application number
NI201800039A
Other languages
English (en)
Inventor
Rudolf Romanie Kesteleyn Bart
Jean-Marie Bernard Raboisson Pierre
François Bonfanti Jean
Hugo Maria Jonckers Tim
Alice Marie-Eve Bardiot Dorothée
Didier M Marchand Arnaud
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of NI201800039A publication Critical patent/NI201800039A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos indólicos mono- o disustituidos, a métodos para prevenir o tratar infecciones virales por dengue utilizando dichoa compuestos y también se refiere a dichos compuestos para su uso como una medicina, más preferentemente para su uso como una medicina para tratar o prevenir infecciones virales por dengue. La presente invención se refiere además a composiciones farmacéuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como una medicina, más preferentemente para la prevención o el tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
NI201800039A 2015-09-16 2018-03-15 Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue NI201800039A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15185523 2015-09-16
EP16163472 2016-04-01

Publications (1)

Publication Number Publication Date
NI201800039A true NI201800039A (es) 2018-07-24

Family

ID=56926217

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800039A NI201800039A (es) 2015-09-16 2018-03-15 Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue

Country Status (29)

Country Link
US (1) US10765662B2 (es)
EP (1) EP3350162B1 (es)
JP (2) JP7050666B2 (es)
KR (1) KR102646174B1 (es)
CN (1) CN108473422B (es)
AU (1) AU2016324982B2 (es)
CA (1) CA2996979C (es)
CL (1) CL2018000696A1 (es)
CO (1) CO2018003471A2 (es)
CR (1) CR20180213A (es)
DK (1) DK3350162T3 (es)
EA (1) EA035663B1 (es)
EC (1) ECSP18020055A (es)
ES (1) ES2893298T3 (es)
HR (1) HRP20211352T1 (es)
HU (1) HUE055870T2 (es)
IL (1) IL258043B (es)
JO (1) JOP20160198B1 (es)
LT (1) LT3350162T (es)
MA (1) MA42810A (es)
MX (1) MX381633B (es)
NI (1) NI201800039A (es)
PE (1) PE20181165A1 (es)
PH (1) PH12018500576A1 (es)
SI (1) SI3350162T1 (es)
TW (1) TWI758255B (es)
UA (1) UA122973C2 (es)
UY (1) UY36903A (es)
WO (1) WO2017046255A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
SI3201176T1 (sl) * 2014-10-01 2019-05-31 Janssen Pharmaceuticals, Inc. Mono-ali di-substituirani derivati indola kot inhibitorji replikacije virusa denga
PL3201177T3 (pl) * 2014-10-01 2019-05-31 Janssen Pharmaceuticals Inc Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3390395T1 (sl) 2015-12-16 2020-11-30 Loxo Oncology, Inc. Spojine uporabne kot inhibitorji kinaz
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
US10646469B2 (en) 2016-03-31 2020-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN109069482B (zh) * 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) * 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI771420B (zh) 2017-05-22 2022-07-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CN119306651A (zh) * 2024-10-11 2025-01-14 山东大学 一种吲哚3-酰胺类衍生物及其制备方法与应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241178T3 (es) 1997-10-27 2005-10-16 Eli Lilly And Company Profarmacos de ester de morlino-n-etilo de inhibidores indolicos de spla 2.
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
WO2003050295A2 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
EP1844042A1 (en) 2005-01-14 2007-10-17 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
EP1853317A2 (en) 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
WO2008119741A2 (en) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
CN102186833A (zh) * 2008-08-18 2011-09-14 耶鲁大学 Mif调节剂
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US8524764B2 (en) 2010-01-15 2013-09-03 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
PE20210470A1 (es) 2014-01-31 2021-03-08 Bristol Myers Squibb Co Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia
SI3201176T1 (sl) 2014-10-01 2019-05-31 Janssen Pharmaceuticals, Inc. Mono-ali di-substituirani derivati indola kot inhibitorji replikacije virusa denga
NO2721243T3 (es) 2014-10-01 2018-10-20
PL3201177T3 (pl) * 2014-10-01 2019-05-31 Janssen Pharmaceuticals Inc Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi
PH12017501272B1 (en) 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX374683B (es) 2015-11-03 2025-03-04 Zoetis Services Llc Compuestos polimericos sol-gel y sus usos.
AU2017245125B2 (en) 2016-03-31 2020-10-22 Takeda Pharmaceutical Company Limited Heterocyclic compound
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
US10646469B2 (en) 2016-03-31 2020-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA128326C2 (uk) 2016-04-01 2024-06-12 Амджен Інк. Химерний рецептор до flt3 та спосіб його застосування
AU2017240788B2 (en) 2016-04-01 2020-04-09 Amgen Inc. Chimeric receptors and methods of use thereof
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
PE20190173A1 (es) 2016-04-01 2019-02-01 Kite Pharma Inc Receptores de antigenos quimericos y celulas t y metodos de uso
CA3018986A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
JP7027329B2 (ja) 2016-04-01 2022-03-01 ビーエーエスエフ ソシエタス・ヨーロピア 二環式化合物
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI771420B (zh) 2017-05-22 2022-07-21 美商健生醫藥公司 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
AU2018274100B2 (en) 2017-05-22 2022-06-23 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
HUE055870T2 (hu) 2021-12-28
JP2021181485A (ja) 2021-11-25
TWI758255B (zh) 2022-03-21
EP3350162B1 (en) 2021-07-14
UA122973C2 (uk) 2021-01-27
ES2893298T3 (es) 2022-02-08
ECSP18020055A (es) 2018-04-30
PE20181165A1 (es) 2018-07-19
CA2996979A1 (en) 2017-03-23
CL2018000696A1 (es) 2018-07-06
PH12018500576A1 (en) 2018-10-15
MA42810A (fr) 2018-07-25
HK1257842A1 (en) 2019-11-01
KR20180052672A (ko) 2018-05-18
IL258043B (en) 2021-08-31
HRP20211352T1 (hr) 2022-02-04
AU2016324982A1 (en) 2018-03-15
CN108473422A (zh) 2018-08-31
DK3350162T3 (da) 2021-10-04
CO2018003471A2 (es) 2018-07-10
JOP20160198B1 (ar) 2022-03-14
EA035663B1 (ru) 2020-07-23
KR102646174B1 (ko) 2024-03-08
AU2016324982B2 (en) 2021-04-15
LT3350162T (lt) 2021-09-27
MX2018003255A (es) 2018-11-09
UY36903A (es) 2017-03-31
US10765662B2 (en) 2020-09-08
SI3350162T1 (sl) 2021-11-30
EA201890722A1 (ru) 2018-09-28
WO2017046255A1 (en) 2017-03-23
JP7050666B2 (ja) 2022-04-08
CN108473422B (zh) 2021-06-15
MX381633B (es) 2025-03-12
EP3350162A1 (en) 2018-07-25
US20180256545A1 (en) 2018-09-13
CA2996979C (en) 2024-01-30
IL258043A (en) 2018-05-31
JP2018528220A (ja) 2018-09-27
TW201722913A (zh) 2017-07-01
CR20180213A (es) 2018-06-27

Similar Documents

Publication Publication Date Title
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
NI201800039A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
NI201800040A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue